Crucell and DSM enter PER.C6 licensing agreement with Chiron

Dutch biotechnology company Crucell N.V. and allied contract manufacturer DSM Biologics have signed a PER.C6 research license agreement for recombinant protein production with Chiron Corporation. This new agreement allows Chiron to evaluate the PER.C6 cell line for use in the manufacturing of Chiron's prophylactic hepatitis C vaccine, which is currently in phase I clinical trials, said a Crucell release.